824 related articles for article (PubMed ID: 16353520)
21. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
22. Leprosy beyond MDT: study of follow-up of 100 released from treatment cases.
Vara N; Agrawal M; Marfatia Y
Indian J Lepr; 2010; 82(4):189-94. PubMed ID: 21434595
[TBL] [Abstract][Full Text] [Related]
23. Analysis of gene probes and gene amplification techniques for diagnosis and monitoring of treatment in childhood leprosy.
Kamal R; Dayal R; Katoch VM; Katoch K
Lepr Rev; 2006 Jun; 77(2):141-6. PubMed ID: 16895070
[TBL] [Abstract][Full Text] [Related]
24. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.
Kroger A; Pannikar V; Htoon MT; Jamesh A; Katoch K; Krishnamurthy P; Ramalingam K; Jianping S; Jadhav V; Gupte MD; Manickam P
Trop Med Int Health; 2008 May; 13(5):594-602. PubMed ID: 18346026
[TBL] [Abstract][Full Text] [Related]
25. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
26. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
27. Risk of relapse in leprosy after fixed-duration multidrug therapy.
Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
[TBL] [Abstract][Full Text] [Related]
28. Relapses in paucibacillary leprosy after MDT--a clinical study.
Grugni A; Nadkarni NJ; Kini MS; Mehta VR
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
[TBL] [Abstract][Full Text] [Related]
29. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
[TBL] [Abstract][Full Text] [Related]
31. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
32. Response of thickened nerve trunks and skin lesions of leprosy patients to MDT.
Porichha D; Rao AK; Nehemaiah E; Mishra MC
Indian J Lepr; 2011; 83(1):31-5. PubMed ID: 21638981
[TBL] [Abstract][Full Text] [Related]
33. Relapses in multibacillary leprosy patients after multidrug therapy.
Poojabylaiah M; Marne RB; Varikkodan R; Bala N; Dandakeri S; Martis J
Lepr Rev; 2008 Sep; 79(3):320-4. PubMed ID: 19009982
[TBL] [Abstract][Full Text] [Related]
34. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
35. Clinico-epidemiological trends of leprosy in Himachal Pradesh: a five year study.
Jindal N; Shanker V; Tegta GR; Gupta M; Verma GK
Indian J Lepr; 2009; 81(4):173-9. PubMed ID: 20704072
[TBL] [Abstract][Full Text] [Related]
36. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Shetty VP; Wakade AV; Ghate SD; Pai VV
Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
[TBL] [Abstract][Full Text] [Related]
37. Detection of viable organisms in leprosy patients treated with multidrug therapy.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Acta Leprol; 1999; 11(3):89-92. PubMed ID: 10544720
[TBL] [Abstract][Full Text] [Related]
38. Lesional characteristics and histopathology in paucibacillary leprosy patients with 2 or 3 skin lesions: comparison between ROM and PB-MDT regimens.
Emmanuel M; Gupte MD
Indian J Lepr; 2005; 77(1):19-25. PubMed ID: 16173416
[TBL] [Abstract][Full Text] [Related]
39. Relapse of leprosy after multidrug therapy.
Dasananjali K
J Med Assoc Thai; 1996 Oct; 79(10):635-9. PubMed ID: 8996998
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
